2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3083 The evolving role of complement genetics in post-renal transplant thrombotic microangiopathy: A single-center retrospective study

Zachary Smith, MD, Mamie Myo Thant, MD MS2, Omar Ammari, MD3, Manish Anand, MD FASN4
1 University of Cincinnati, Cincinnati, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 University of Cincinnati, Cincinnati, OH, United States
4 Cumberland Nephrology Associates, Vineland, New Jersey, United States

Introduction - Thrombotic microangiopathy (TMA) can be a sequela of uncontrolled endothelial damage. Kidney transplantation (KTx) is highly complement-activating, due to factors such as ischemia-reperfusion injury and HLA- and ABO-mismatch between donor and recipient (Mirioglu S et al, CKJ 2026). Post-KTx TMAs compromise allograft survival, however identifying patients who need longer therapy with terminal complement inhibition (CI) is challenging.

Complement-mediated TMA (CM-TMA) develops through two hits: a genetic predisposition towards complement dysregulation, followed by a complement-activating trigger (such as KTx). Here we present the results of a single-center retrospective cohort study of adult patients who underwent KTx and then developed systemic TMA and/or TMA on renal allograft biopsy. Our center performed genetic testing to identify complement pathway defects, in addition to various serum complement biomarkers. We propose that the presence or absence of a complement regulatory factor defect on genotyping may help predict the duration of CI needed to prevent allograft failure.

Methods – Patients were identified retrospectively through 1) a database of patients with glomerular diseases maintained by the nephrology department at the University of Cincinnati; and/or 2) a database of patients who received inpatient eculizumab, maintained by the UC pharmacy group since 2016.

Results – From 2016-2025, 26 post-transplant CM-TMA cases were identified. 13 patients were women and 13 were men, with ages ranging from 28 to 68 years (median 53 years). 7 patients had schistocytes on peripheral blood smear, with kidney biopsy either not done or showing no TMA; 9 patients had no schistocytes on smear but evidence of TMA on kidney biopsy; and 10 patients had both schistocytes on smear and a kidney biopsy with TMA.

18 patients among the above had genetic testing to evaluate for CM-TMA-predisposing mutations. 5 patients had no genetic complementopathy. Among these 5 patients, the median duration of CI was 4 weeks. The patient with the longest duration of CI in this group (8 weeks) ultimately passed from sepsis. 2 patients in this group experienced graft failure and 2 patients maintained allograft function.

Known pathogenic mutations in complement regulatory genes were found in 4 patients: 2 were heterozygous for mutations in CFH, while two were homozygous for CFHR3-CFHR1 deletions. These patients were treated with longer courses of CI, some surpassing 6 months. Neither patient with the CFHR3-CFHR1 deletion was found to have anti-factor H autoantibodies.

VUS (variants of uncertain significance) in complement regulatory genes were found in 9 patients, including the CFH gene (1 patient), heterozygous deletion of CFHR1 (1), heterozygous deletions in CFHR3-CFHR1 (4), heterozygous mutation in CFI (1), heterozygous frameshift mutation in CFHR5 (1), heterozygous deletion of CFHR1-CFHR4 (1). Of these, 7 patients were treated with CI with duration ranging from 4 weeks to 250 weeks (median 12w, mean 77w). 2 patients with VUS did not receive CI. None of the patients with VUS experienced loss of graft function, although one experienced recurrence in the graft that resolved with rescue CI.

sC5b-9 was measured in 4 patients at the time of their TMA diagnosis and was found to be elevated above the normal range in 3, including one patient with a heterozygous VUS in CFH, one patient with a homozygous CFHR3-CFHR1 deletion, and one patient who did not have genetic testing. One patient was treated with CI despite a normal sC5b-9 level and found to have a heterozygous CFHR3-CFHR1 deletion.

Discussion - Our cohort of post-KTx TMA patients was enriched in deletions of complement factor H-related proteins in the absence of anti-factor H autoantibodies. While these deletions of CFHR are of relatively high prevalence in the general population with no noted adverse sequelae (de Cordoba, Immunological Reviews, 2023), their import in the presence of post-KTx TMA is unclear. Complement biomarkers were also tested, but we were unable to evaluate any trends. Overall, our findings suggest that in post-KTx TMA patients with VUS, a shorter duration of CI may be considered, compared to those with known pathogenic variants in complement genes. More research into robust, accessible, and high throughput functional complement assays, as well as a larger cohort of genetically characterized patients, are both needed.

Mamie Myo Thant, MD MS: Velico Medical - Research Funding; Terumo - Consultancy (Includes expert testimony)